← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Reveragen Biopharma, Inc.
Rockville, VA
$12,586,701
Total funding
11
Grants
Funding over time
peak $2.3M · FY2010–24$2.5M$1.9M$1.3M$625K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$11,385,465 · 10
FDA$1,201,236 · 1
By mechanism
R44$6,100,837 · 1
SB1$3,352,543 · 1
R41$1,529,044 · 6
R01$1,201,236 · 1
R43$403,041 · 2
Investigators at Reveragen Biopharma, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
Commercialization Readiness Pilot (CRP) to maximize vamorolone international labeling and sales$1,680,179
SB1 · FY2020 · NS
Commercialization Readiness Pilot (CRP) to maximize vamorolone international labeling and sales$1,672,364
SB1 · FY2021 · NS
Pivotal trial of vamorolone in Duchenne muscular dystrophy$1,500,000
R44 · FY2018 · NS
Pivotal trial of vamorolone in Duchenne muscular dystrophy$1,499,060
R44 · FY2019 · NS
Phase IIa study of VBP15 for Duchenne muscular dystrophy$1,496,525
R44 · FY2017 · NS
Phase IIa study of VBP15 for Duchenne muscular dystrophy$1,495,253
R44 · FY2016 · NS
Vamorolone trial in Becker muscular dystrophy$601,151
R01 · FY2024 · FD
Vamorolone trial in Becker muscular dystrophy$600,085
R01 · FY2021 · FD
Anti-inflammatory and Mitotic Properties of Non-hormonal Steroids in Lung Epithel$375,244
R41 · FY2010 · HL
Effectiveness of VBP15, a dissociative steroidal analogue, on chronic inflammation in a mouse model of multiple sclerosis$253,802
R41 · FY2016 · AI
Effect of VBP15, a dissociative steroidal analogue, on intestinal epithelial repair processes in inflammatory bowel disease$225,000
R41 · FY2014 · DK
Effectiveness of VBP15, a dissociative steroidal analogue, on inflammation in a mouse model of arthritis$225,000
R41 · FY2015 · AR
Definition of pharmacodynamic biomarkers for juvenile dermatomyositis for clinical trials$225,000
R43 · FY2018 · AR
Evaluation of VBP15 a dissociative steroidal analogue on pain and inflammation$225,000
R41 · FY2014 · MD
Building an evidentiary case for circulating GHBP as a biomarker for drug-associated stunting of growth$224,998
R41 · FY2018 · HD
Establishing a biomarker framework for feasibility studies of vamorolone in vasculitis$178,041
R43 · FY2018 · AR
Establishing a Cost-effective Return of Results to Parents of Boys in VISION-DMD Clinical Trials$109,999
R44 · FY2019 · NS